Roche CEO and member of the Corporate Executive Committee, Daniel O’Day, will step down its role as of 31 December 2018. He will provide support to the company for a smooth transition until the end of February 2019, to then become the new Chairman of the Board and Chief Executive Officer of Gilead Sciences, effective March 1, 2019. O’Day has held the position in Roche since 2012, and prior to that led Roche Diagnostics.
The new CEO of Roche starting 1 January 2019 will be William (Bill) Anderson, currently CEO of Genentech; he will be based in Basel, report to Severin Schwan, Roche Group CEO and become a member of the Corporate Executive Committee. Bill Anderson joined the Group in 2006 as lead of the Immunology Business Unit in Genentech, to then took responsibility for Oncology Sales and Marketing. In 2013, he was appointed Head of Global Product Strategy based in Basel, and became CEO of Genentech in 2017. Bill Anderson holds Master of Science degrees in Management and Chemical Engineering from Massachusetts Institute of Technology.